350 related articles for article (PubMed ID: 28086964)
1. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.
Spencer B; Valera E; Rockenstein E; Overk C; Mante M; Adame A; Zago W; Seubert P; Barbour R; Schenk D; Games D; Rissman RA; Masliah E
Acta Neuropathol Commun; 2017 Jan; 5(1):7. PubMed ID: 28086964
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.
El-Agnaf O; Overk C; Rockenstein E; Mante M; Florio J; Adame A; Vaikath N; Majbour N; Lee SJ; Kim C; Masliah E; Rissman RA
Neurobiol Dis; 2017 Aug; 104():85-96. PubMed ID: 28476636
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.
Kim C; Spencer B; Rockenstein E; Yamakado H; Mante M; Adame A; Fields JA; Masliah D; Iba M; Lee HJ; Rissman RA; Lee SJ; Masliah E
Mol Neurodegener; 2018 Aug; 13(1):43. PubMed ID: 30092810
[TBL] [Abstract][Full Text] [Related]
4. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.
Rockenstein E; Ostroff G; Dikengil F; Rus F; Mante M; Florio J; Adame A; Trinh I; Kim C; Overk C; Masliah E; Rissman RA
J Neurosci; 2018 Jan; 38(4):1000-1014. PubMed ID: 29246926
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
[TBL] [Abstract][Full Text] [Related]
6. α-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies.
Prots I; Grosch J; Brazdis RM; Simmnacher K; Veber V; Havlicek S; Hannappel C; Krach F; Krumbiegel M; Schütz O; Reis A; Wrasidlo W; Galasko DR; Groemer TW; Masliah E; Schlötzer-Schrehardt U; Xiang W; Winkler J; Winner B
Proc Natl Acad Sci U S A; 2018 Jul; 115(30):7813-7818. PubMed ID: 29991596
[TBL] [Abstract][Full Text] [Related]
7. Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.
Spencer B; Desplats PA; Overk CR; Valera-Martin E; Rissman RA; Wu C; Mante M; Adame A; Florio J; Rockenstein E; Masliah E
J Neurosci; 2016 Jul; 36(30):7971-84. PubMed ID: 27466341
[TBL] [Abstract][Full Text] [Related]
8. Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.
Spencer B; Trinh I; Rockenstein E; Mante M; Florio J; Adame A; El-Agnaf OMA; Kim C; Masliah E; Rissman RA
Neurobiol Dis; 2019 Jul; 127():163-177. PubMed ID: 30849508
[TBL] [Abstract][Full Text] [Related]
9. Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy.
Schaser AJ; Stackhouse TL; Weston LJ; Kerstein PC; Osterberg VR; López CS; Dickson DW; Luk KC; Meshul CK; Woltjer RL; Unni VK
Acta Neuropathol Commun; 2020 Aug; 8(1):150. PubMed ID: 32859276
[TBL] [Abstract][Full Text] [Related]
10. Higher levels of myelin phospholipids in brains of neuronal α-Synuclein transgenic mice precede myelin loss.
Grigoletto J; Pukaß K; Gamliel A; Davidi D; Katz-Brull R; Richter-Landsberg C; Sharon R
Acta Neuropathol Commun; 2017 May; 5(1):37. PubMed ID: 28482862
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.
Williams GP; Schonhoff AM; Jurkuvenaite A; Thome AD; Standaert DG; Harms AS
J Neuroinflammation; 2018 Aug; 15(1):244. PubMed ID: 30165873
[TBL] [Abstract][Full Text] [Related]
12. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease.
Kim S; Kwon SH; Kam TI; Panicker N; Karuppagounder SS; Lee S; Lee JH; Kim WR; Kook M; Foss CA; Shen C; Lee H; Kulkarni S; Pasricha PJ; Lee G; Pomper MG; Dawson VL; Dawson TM; Ko HS
Neuron; 2019 Aug; 103(4):627-641.e7. PubMed ID: 31255487
[TBL] [Abstract][Full Text] [Related]
13. Naturally occurring autoantibodies against α-synuclein rescues memory and motor deficits and attenuates α-synuclein pathology in mouse model of Parkinson's disease.
Huang YR; Xie XX; Ji M; Yu XL; Zhu J; Zhang LX; Liu XG; Wei C; Li G; Liu RT
Neurobiol Dis; 2019 Apr; 124():202-217. PubMed ID: 30481547
[TBL] [Abstract][Full Text] [Related]
14. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
15. A role for α-Synuclein in axon growth and its implications in corticostriatal glutamatergic plasticity in Parkinson's disease.
Schechter M; Grigoletto J; Abd-Elhadi S; Glickstein H; Friedman A; Serrano GE; Beach TG; Sharon R
Mol Neurodegener; 2020 Mar; 15(1):24. PubMed ID: 32228705
[TBL] [Abstract][Full Text] [Related]
16. Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression.
Fischer DL; Manfredsson FP; Kemp CJ; Cole-Strauss A; Lipton JW; Duffy MF; Polinski NK; Steece-Collier K; Collier TJ; Gombash SE; Buhlinger DJ; Sortwell CE
Sci Rep; 2017 Nov; 7(1):16356. PubMed ID: 29180681
[TBL] [Abstract][Full Text] [Related]
17. Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies.
Overk CR; Cartier A; Shaked G; Rockenstein E; Ubhi K; Spencer B; Price DL; Patrick C; Desplats P; Masliah E
Mol Neurodegener; 2014 May; 9():18. PubMed ID: 24885390
[TBL] [Abstract][Full Text] [Related]
18. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease.
Wang Z; Gao G; Duan C; Yang H
Biomed Pharmacother; 2019 Jul; 115():108843. PubMed ID: 31055236
[TBL] [Abstract][Full Text] [Related]
19. Investigating the neuroprotective effect of AAV-mediated β-synuclein overexpression in a transgenic model of synucleinopathy.
Sargent D; Bétemps D; Drouyer M; Verchere J; Gaillard D; Arsac JN; Lakhdar L; Salvetti A; Baron T
Sci Rep; 2018 Dec; 8(1):17563. PubMed ID: 30510219
[TBL] [Abstract][Full Text] [Related]
20. Internalization, axonal transport and release of fibrillar forms of alpha-synuclein.
Bieri G; Gitler AD; Brahic M
Neurobiol Dis; 2018 Jan; 109(Pt B):219-225. PubMed ID: 28323023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
